Nandini C. Patel

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

Viral Diagnostics, Worldwide Outbreak, Immunology +16

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

W. Gregory Roberts, Ethan Ung, Pamela Whalen et al. · Cancer Research · 2008 · 379 citations · Full text

Antitumor Activity, Cell Adhesion, Focal Adhesion Plaques +18

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

Michael J. Munchhof, Qifang Li, Andrei Shavnya et al. · ACS Medicinal Chemistry Letters · 2011 · 158 citations · Full text

Pharmaceutical Science, Chemoprevention Strategy, Smoothened Inhibitor +20

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

Heather Eng, Alyssa Dantonio, Eugene P. Kadar et al. · Drug Metabolism and Disposition · 2022 · 111 citations · Full text

Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration

Bo Feng, Mark A. West, Nandini C. Patel et al. · Journal of Pharmaceutical Sciences · 2019 · 97 citations

Neuro-oncology, Neuroimaging Biomarkers, Neurophysiology +13